DALLAS, July 15, 2009 (GLOBE NEWSWIRE) -- InvestorSoup.com announces an investment report featuring Hemispherex Biopharma Inc. (AMEX:HEB). The report includes financial and investment analysis, analyst consensus, and pertinent industry information you need to know to make an educated investment decision.
The investment report on Hemispherex Biopharma Inc. (AMEX:HEB) should be of particular interest to other pharmaceutical companies: Gilead Sciences Inc. (Nasdaq:GILD), Biogen Idec Inc. (Nasdaq:BIIB), Teva Pharmaceutical Industries (Nasdaq:TEVA) and Life Technologies Corp. (Nasdaq:LIFE).
It is available at: http://investorsoup.com/lp/HEB/
Read and post on Twitter and top Stock Message Boards for these stocks and more, all in real-time: http://www.BoardCentral.com/
Hemispherex Biopharma Inc. (AMEX: HEB) is a developer, maker and distributor of natural immune system drug therapies for the treatment of a variety of viral and immune-based disorders. The biopharmaceutical Company's new drug therapies include Ampligen, and Alferon N and Injection. Ampligen is currently under early clinically development for the treatment of Chronic Fatigue Syndrome (CFS).
In the report, the analyst notes:
"In the case of HEB, however, successful monetization of its product line lies in the Company's most timely development of its Ampligen candidate, an experimental therapeutic for the H5N1 virus. The PolyI:PolyC12U has been noted by the publication Therapeutics and Clinical Risk Management as the lead adjuvant candidate for mucosal vaccines. The publication said Ampligen was "extremely important" in studies of the drug, as the drug produced "cross-protection" against variant influenza viruses.
To read the entire report visit: http://investorsoup.com/lp/HEB/
InvestorSoup.com is a small-cap research and investment commentary provider. InvestorSoup strives to provide a balanced view of many promising small-cap companies that would otherwise fall under the radar of the typical Wall Street investor. We provide investors with an excellent first step in their research and due diligence by providing daily trading ideas, and consolidating the public information available on them. For more information on InvestorSoup, please visit http://www.InvestorSoup.com
InvestorSoup Disclosure
InvestorSoup.com is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell any securities. InvestorSoup.com is a Web site wholly-owned by BlueWave Advisors, LLC. Please read our report and visit our Web site, InvestorSoup.com, for complete risks and disclosures.